Detection and Quantification of Epstein-Barr Virus

LightUp Technologies AB and DakoCytomation A/S have announced the market introduction of ReSSQ™ EBV Assay, a nucleic acid test (NAT) for detection and quantification of Epstein-Barr virus. The assay provides a rapid and accurate means of monitoring viral load of EBV in clinical specimens. Currently, it is validated for use in conjunction with the LightCycler® and ABI PRISM® 7000 SDS real-time PCR instrument platforms.

Ulrica Sehlstedt, Ph.D., Chief Executive Officer, commented, 'The ReSSQ EBV Assay represents the most recent addition to our developing portfolio of products for infectious disease diagnostics. It follows our strategy to provide clinical laboratories with robust and cost effective diagnostic kits. As one component in the prevention of disease and management of infections, we are proud of being able to provide the healthcare community with an efficient and easy to use tool to monitor viral load before, during and after treatment of patients with EBV.'

In June, LightUp Technologies and DakoCytomation announced a European distribution agreement. Under the agreement, ReSSQ EBV Assay will be marketed and sold by DakoCytomation in Europe. Eventually, the assay will be made available throughout the world.

Geoff Gower, Director of Microbiology at DakoCytomation, said, 'We are happy to make this product available to clinicians and clinical laboratories involved in the management of immunocompromised patients. EBV infection is, for example, a major risk factor for developing lymphoproliferative disease (PTLD), a life-threatening complication of organ transplantation.'